bioRxiv Science⌕ Search

Biology subjects

Taddei-Tardon, M.

Publications and source records attributed to Taddei-Tardon, M..

2 recordsLinked to original sources

Integrated 5-HT2A-TrkB and G protein signaling in serotonergic psychedelic responses

Serotonergic psychedelics have attracted considerable interest as promising therapeutic agents. However, the molecular mechanisms linking their acute hallucinogenic-like effects to longer-lasting neuroplastic responses remain incompletely understood, partly because of the scarcity of native neural models suitable for mechanistic studies. Here, we developed a neural stem cell-derived in vitro model capable of differentiating into neuronal and glial lineages and, after characterization, used it to investigate the molecular pharmacology of serotonergic psychedelics. A panel comprising tryptamines, phenethylamines and ergolines, including psychedelic compounds and selected non-psychedelic analogues, was evaluated alongside ketamine and TrkB agonists. Endpoints included dendritogenesis, synaptogenesis, immediate-early gene induction, BDNF expression and lactate production. TrkB silencing abolished dendritogenic responses to serotonergic psychedelics, ketamine and TrkB agonists, whereas 5-HT2A receptor silencing selectively impaired serotonergic psychedelic-induced plasticity and altered TrkB-dependent responses. Most serotonergic compounds also increased synaptogenesis and induced c-Fos and Egr-2 expression, although ligand-specific differences were evident, particularly for psilocin and the phenethylamines DOI and Ariadne. Uncoupling of Gq/11 or Gi/o protein-dependent signaling differentially modified neuroplastic and transcriptional responses, indicating a ligand and endpoint dependent contribution of both pathways. Serotonergic psychedelics further induced a 5-HT2A receptor dependent lactate response that was generally sensitive to disruption of either Gq/11 or Gi/o protein coupling. Taken together, these findings support a model in which serotonergic psychedelics recruit an integrated 5-HT2A-TrkB signaling network with distinct structural, transcriptional and metabolic outputs, and establish this neural stem cell-derived system as a valuable platform for screening and dissecting the signaling basis of psychedelic action.

neuroscience↗

Quantitative phosphoproteomics uncovers the signalling dynamics of hallucinogenic psychedelics

Psychedelic drugs can induce intense changes in perception and thought, and some also promote long-lasting adaptations in brain circuits that are being explored for treatment of mood and anxiety disorders. How these compounds differ at the level of intracellular signalling, and how hallucinogenic drugs diverge from related non-hallucinogenic forms, is poorly understood. A central question is whether a shared molecular fingerprint distinguishes hallucinogenic psychedelic action from other forms of receptor activation in neurons. Here, we show that chemically diverse psychedelics trigger a coordinated reorganisation of phosphorylation patterns across many proteins in neural cells, and that this global signalling response contains a distinct signature that separates hallucinogenic compounds from non-hallucinogenic counterparts of similar structure. We use a glycolysis-regulating transcription factor as an example of the signatures functional relevance to show that hallucinogenic psychedelics, but not their non-hallucinogenic analogues, enhance markers of glycolytic metabolism. These findings reveal that hallucinogenic and non-hallucinogenic psychedelics engage separable intracellular architectures, and establish a framework for understanding how different psychoactive compounds couple receptor activation to specific cellular states. More broadly, this work opens a path to using signalling fingerprints to guide the design of psychedelic-inspired therapeutics with tailored behavioural and metabolic profiles.

neuroscience↗